Proteins

Inhibitors

Azido-PEG8-acid


Cat. No.: HY-140454 CAS No.: 1214319-92-2 Molecular Formula: $C_{19}H_{37}N_3O_{10}$ 467.51 Molecular Weight:

Target: ADC Linker; PROTAC Linkers

Pathway: Antibody-drug Conjugate/ADC Related; PROTAC

4°C, sealed storage, away from moisture Storage:

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (213.90 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
	1 mM	2.1390 mL	10.6950 mL	21.3899 mL	
	5 mM	0.4278 mL	2.1390 mL	4.2780 mL	
	10 mM	0.2139 mL	1.0695 mL	2.1390 mL	

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

BIOLOGICAL ACTIVITY

escription
escription

IC₅₀ & Target

Azido-PEG8-acid is a non-cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG8-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. Azido-PEG8-acid is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

	0		0

Non-cleavable Linker

In Vitro ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker^[1].

PEGs

Page 1 of 2

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tan M, et al. Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules. 2010 Mar 8;11(3):754-61.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com